Health Care & Life Sciences » Pharmaceuticals | Knight Therapeutics Inc.

Knight Therapeutics Inc. | Ownership

Companies that own Knight Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
CI Investments, Inc.
9,103,372
6.38%
809,432
0.13%
06/29/2018
Fidelity (Canada) Asset Management ULC
6,288,600
4.4%
325,000
0.06%
07/31/2018
QV Investors, Inc.
4,115,550
2.88%
253,400
0.7%
08/31/2018
Janus Capital Management LLC
3,027,599
2.12%
3,296
0.18%
06/30/2018
BMO Asset Management, Inc.
2,317,143
1.62%
606,525
0.02%
03/31/2018
Dimensional Fund Advisors LP
1,903,232
1.33%
55,590
0%
06/29/2018
GWL Investment Management
1,835,954
1.29%
157,353
0.03%
06/30/2018
PenderFund Capital Management Ltd.
1,711,200
1.2%
1,711,200
2.63%
06/30/2018
BC Investment Management Corp.
1,230,589
0.86%
471,850
0.02%
03/31/2017
Mackenzie Financial Corp.
1,066,485
0.75%
89,200
0.01%
09/06/2018

About Knight Therapeutics

View Profile
Address
3400, de Maisonneuve Boulevard West
Montréal Québec H3Z 3B8
Canada
Employees -
Website http://www.gud-knight.com
Updated 07/08/2019
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.